Search clinical trials for: E3 - mFOLFOX6, durvalumab and monalizumab

Total 1441 results

MedImmune LLC

Withdrawn

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Microsatellite-stable Colorectal Cancer
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
MedImmune LLC

Active, not recruiting

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Advanced Solid Tumors

United States, Spain, Belgium, Italy, Korea, Republic of, Canada, Australia, Hungary, United Kingdom, France, New Zealand
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
Centre Georges Francois Leclerc
AstraZeneca

Completed

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (MEDITREME)

Colorectal Cancer Metastatic

France
Five Prime Therapeutics, Inc.

Completed

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (FIGHT)

Gastric Cancer | Gastrointestinal Cancer | Gastrointestinal Cancer Metastatic

United States
Liz-Anne Lewsley
AstraZeneca; NHS Greater Glasgow and Clyde; University of Glasgow

Not yet recruiting

A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer (PRIME-RT)

Rectal Cancer | Rectal Neoplasms | Rectal Adenocarcinoma
Five Prime Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

Gastric Cancer

United States, Spain, China, Italy, Korea, Republic of, Portugal, Taiwan, Japan, Turkey, France, Hungary, Thailand, Germany, Poland, Australia, Belgium, Romania, United Kingdom
University of Michigan

Completed

Phase 1A Study of the Safety of KSP/QRH Dimer

Healthy Adults

United States
Fudan University

Not yet recruiting

Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Colorectal Cancer | Liver Metastases

China
Assistance Publique Hopitaux De Marseille

Recruiting

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)

Non-small Cell Lung Cancer

France
Rush University Medical Center
Novartis Pharmaceuticals

Recruiting

Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate (E3)

Hypertension

United States
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Esophagus Adenocarcinoma

Germany
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Ain Shams University

Recruiting

the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Gastrointestinal Cancer

Egypt
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis (CANWATCH)

Colorectal Cancer | Adjuvant Chemotherapy

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI)

MSI | dMMR Colorectal Cancer

France
Rui-hua Xu, MD, PhD

Not yet recruiting

A Phase II Study of Surufatinib Combined With PD-L1 and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Advanced Pancreatic Cancer

China
Hirva Mamdani
AstraZeneca; Barbara Ann Karmanos Cancer Institute

Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Small Cell Lung Cancer | SCLC | Extensive Stage Small Cell Lung Cancer

United States
AstraZeneca
Kappa Santé

Recruiting

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. (ARSENAL)

Small Cell Lung Carcinoma

France
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
Xu jianmin

Unknown

Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer

Neoplasm Metastasis | Liver Neoplasms | Colorectal Neoplasms

China
Hark Kyun Kim

Recruiting

Vactosertib and Durvalumab in Gastric Cancer

Stomach Neoplasm

Korea, Republic of
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
Yonsei University

Completed

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Sarcoma

Korea, Republic of
NSABP Foundation Inc

Completed

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Rectal Cancer

United States
MedImmune LLC

Completed

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Respiratory Syncytial Virus Infections | Chronic Lung Disease and <= 24 Months of Age or | Premature With Gestational Age <=35 Weeks and <=6 Months of Age

Australia, Chile, New Zealand
Institut Paoli-Calmettes
Innate Pharma

Unknown

Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (PIRAT)

Hematologic Malignancies

France
Oslo University Hospital
AstraZeneca

Active, not recruiting

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (DART)

Cancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage III

Norway, Finland, Lithuania, Estonia
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
Yonsei University

Not yet recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Non Small Cell Lung Cancer

Korea, Republic of
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
John L. Villano, MD, PhD

Active, not recruiting

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Tumor, Solid

United States
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Active, not recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Thyroid Cancer

United States
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Solid Malignancies

Canada
University of Texas Southwestern Medical Center
AstraZeneca

Active, not recruiting

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Lung Cancer Stage III

United States
AstraZeneca

Completed

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Advanced Malignancy

China
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca; Vall d'Hebron Institute of Oncology (VHIO)

Recruiting

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC)

Rectal Cancer

Spain
Institut Cancerologie de l'Ouest
AstraZeneca

Active, not recruiting

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) (POSTCARD)

Bone Metastases | Prostate Cancer Patients | Node; Prostate

France
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
AstraZeneca

Active, not recruiting

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) (TopDouble)

Biliary Tract Cancers

China
Institut Claudius Regaud

Active, not recruiting

A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation (SILK BM)

NSCLC

France
AstraZeneca

Completed

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
Martin-Luther-Universität Halle-Wittenberg
GALMED GmbH

Completed

TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) (AIO-KRK-0111)

Colorectal Cancer

Germany

Search clinical trials for: E3 - mFOLFOX6, durvalumab and monalizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations